Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

被引:86
|
作者
Zivadinov, R. [1 ,2 ]
Bergsland, N. [1 ]
Dolezal, O. [3 ,4 ]
Hussein, S. [1 ]
Seidl, Z. [5 ]
Dwyer, M. G. [1 ]
Vaneckova, M. [5 ]
Krasensky, J. [5 ]
Potts, J. A. [7 ]
Kalincik, T. [3 ,4 ,6 ]
Havrdova, E. [3 ,4 ]
Horakova, D. [3 ,4 ]
机构
[1] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Buffalo, NY 14203 USA
[2] SUNY Buffalo, Jacobs Neurol Inst, Buffalo, NY 14203 USA
[3] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Radiol, Prague, Czech Republic
[6] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Melbourne, Vic 3010, Australia
[7] Biogen Idec Inc, Weston, MA USA
关键词
GRAY-MATTER ATROPHY; CLINICALLY ISOLATED SYNDROMES; VOXEL-BASED ANALYSIS; MULTIPLE-SCLEROSIS; BRAIN ATROPHY; GREY-MATTER; INTERFERON BETA-1A; MODERN VIEWS; FOLLOW-UP; IMAGES;
D O I
10.3174/ajnr.A3503
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.
引用
收藏
页码:1931 / 1939
页数:9
相关论文
共 50 条
  • [1] Myelin dynamics in the spinal cord predict cord atrophy and disability progression at 5-years in early relapsing-remitting MS
    Gaubert, Malo
    Combes, Benoit
    Bannier, Elise
    Masson, Arthur
    Caron, Vivien
    Baudron, Gaelle
    Ferre, Jean-Christophe
    Le Page, Emmanuelle
    Stankoff, Bruno
    Edan, Gilles
    Bodini, Benedetta
    Kerbrat, Anne
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 254 - 255
  • [2] Subcortical but Not Cortical Gray Matter Atrophy Predicts Disability Progression over 5 Years in Patients with Early Relapsing-Remitting Multiple Sclerosis
    Zivadinov, Robert
    Bergsland, Niels
    Dolezal, Ondrej
    Hussein, Sara
    Seidl, Zdenek
    Dwyer, Michael
    Vaneckova, Manuela
    Krasensky, Jan
    Potts, James
    Havrdova, Eva
    Horakova, Dana
    NEUROLOGY, 2012, 78
  • [3] Measuring disability in relapsing-remitting MS
    Rudick, Richard A.
    Kappos, Ludwig
    NEUROLOGY, 2010, 75 (04) : 296 - 297
  • [4] Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study
    Zivadinov, Robert
    Tekwe, Carmen
    Bergsland, Niels
    Dolezal, Ondrej
    Havrdova, Eva
    Krasensky, Jan
    Dwyer, Michael G.
    Seidl, Zdenek
    Ramasamy, Deepa P.
    Vaneckova, Manuela
    Horakova, Dana
    MULTIPLE SCLEROSIS INTERNATIONAL, 2013, 2013
  • [5] Natalizumab arrests cortical atrophy progression in relapsing-remitting multiple sclerosis
    Rinaldi, F.
    Calabrese, M.
    Mattisi, I.
    Seppi, D.
    Puthenparampil, M.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S195 - S196
  • [6] Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis
    Hofstetter, Louis
    Naegelin, Yvonne
    Filli, Lukas
    Kuster, Pascal
    Traud, Stefan
    Smieskova, Renata
    Mueller-Lenke, Nicole
    Kappos, Ludwig
    Gass, Achim
    Sprenger, Till
    Penner, Iris-Katharina
    Nichols, Thomas E.
    Vrenken, Hugo
    Barkhof, Frederik
    Polman, Chris
    Radue, Ernst-Wilhelm
    Borgwardt, Stefan J.
    Bendfeldt, Kerstin
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (02) : 202 - 213
  • [7] The rate of cortical atrophy progression distinguishes "benign" MS from early relapsing-remitting MS. A five-year longitudinal study
    Calabrese, M.
    Mattisi, I.
    Atzori, M.
    Favaretto, A.
    Rinaldi, F.
    Grossi, P.
    Puthenparampil, M.
    Federle, L.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S68 - S68
  • [8] Thalamus atrophy predicting cognitive impairment in early relapsing-remitting multiple sclerosis patients
    Ignacio Rojas, Juan
    Francisco, Sanchez
    Patrucco, Liliana
    Miguez, Jimena
    Cristiano, Edgardo
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 169 - 169
  • [9] Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis A 5-year longitudinal study
    Horakova, Dana
    Dwyer, Michael G.
    Havrdova, Eva
    Cox, Jennifer L.
    Dolezal, Ondrej
    Bergsland, Niels
    Rimes, Brett
    Seidl, Zdenek
    Vaneckova, Manuela
    Zivadinov, Robert
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 282 (1-2) : 112 - 119
  • [10] Classifying silent progression in relapsing-remitting MS
    Filippi, Massimo
    Rocca, Maria A.
    NATURE REVIEWS NEUROLOGY, 2019, 15 (06) : 315 - 316